Atsuta Ryo, To Yasuo, Sakamoto Susumu, Mukai Isao, Kobayashi Akihiro, Kinoshita Arisa, Takahashi Kazuhisa
Department of Respiratory Medicine, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan.
Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, Tokyo, Japan.
Allergol Int. 2017 Jul;66(3):411-417. doi: 10.1016/j.alit.2016.09.001. Epub 2016 Oct 3.
Maintaining high treatment adherence levels is critical for effective management of chronic diseases. The Adherence Starts with Knowledge 20 (ASK-20) questionnaire is the only linguistically validated patient-reported treatment adherence tool available in Japan. We conducted additional analyses on ASK-20 data from Japanese adults with asthma.
This was a prospective, non-interventional, single-visit, multi-centre study in Japanese adults (n = 300) with asthma receiving long-term treatment with inhaled corticosteroids (ICS) or ICS/long-acting beta-agonists. We tested the reliability, validity and the relationship between different adherence conditions and ASK-20 score. At one centre, ICS adherence prescription rate was calculated retrospectively based on 2-year percentage ICS adherence data contained within medical records.
The ASK-20 had good internal consistency reliability (Cronbach's alpha = 0.76; n = 290). Discriminant validity was demonstrated with significant correlations between the percentage ICS adherence rates and both the mean ASK-20 total score and mean total barrier count (TBC) (r = -0.51 and -0.58, p < 0.001; n = 111). The ASK-20 total score discriminated between subjects with good and poor adherence measured by patients' reported questionnaire and between those of high and low percentage ICS adherence rates. All other factors that possibly affect adherence were correlated with the mean ASK-20 total score and mean TBC in addition to the number of medicines taken every day.
The Japanese ASK-20 is a reliable tool for assessing possible medication adherence barriers and adherence behaviour in Japanese adults with asthma. Furthermore, our results are comparable with those obtained using the ASK-20 in the United States.
维持较高的治疗依从性水平对于慢性病的有效管理至关重要。“依从始于知识20”(ASK - 20)问卷是日本唯一经过语言验证的患者报告的治疗依从性工具。我们对日本成年哮喘患者的ASK - 20数据进行了额外分析。
这是一项针对接受吸入性糖皮质激素(ICS)或ICS/长效β受体激动剂长期治疗的日本成年哮喘患者(n = 300)的前瞻性、非干预性、单次就诊、多中心研究。我们测试了可靠性、有效性以及不同依从性状况与ASK - 20评分之间的关系。在一个中心,基于病历中包含的2年ICS依从性百分比数据,回顾性计算ICS依从性处方率。
ASK - 20具有良好的内部一致性可靠性(Cronbach's α = 0.76;n = 290)。通过ICS依从率百分比与ASK - 20总分均值和总障碍计数(TBC)均值之间的显著相关性证明了判别效度(r = -0.51和 -0.58,p < 0.001;n = 111)。ASK - 20总分在通过患者报告问卷测量的依从性良好和不良的受试者之间以及ICS依从率百分比高和低的受试者之间进行了区分。除了每天服用的药物数量外,所有其他可能影响依从性的因素均与ASK - 20总分均值和TBC均值相关。
日本版ASK - 20是评估日本成年哮喘患者可能的药物依从性障碍和依从行为的可靠工具。此外,我们的结果与在美国使用ASK - 20获得的结果具有可比性。